查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011533

人類微生物組市場：按類型、部位、應用和最終用戶分類－2026-2032年全球市場預測

Human Microbiome Market by Type, Target Microbiome Site, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，人類微生物組市場價值將達到 24.1 億美元，到 2026 年將成長到 29.8 億美元，到 2032 年將達到 114 億美元，年複合成長率為 24.83%。

主要市場統計數據
基準年 2025 24.1億美元
預計年份：2026年 29.8億美元
預測年份 2032 114億美元
複合年成長率 (%) 24.83%

這篇全面的介紹重點闡述了人類微生物組的基本作用、歷史演變和戰略重要性，揭示了其整體情況。

人類微生物組已迅速從曇花一現的科學興趣發展成為理解人類健康、疾病預防和治療方法創新的基礎要素。這本全面的導論詳細說明了棲息表人體內外的複雜微生物群落如何影響免疫調節、代謝調控和神經路徑。透過說明微生物組檢驗的突破性發現和關鍵里程碑，讀者將了解從早期培養為基礎的研究到高通量定序和多體學整合的歷程。

透過技術突破、政策進步和策略合作，找出能夠徹底改變人類微生物組格局的變革性變化。

人類微生物組的快速演變的核心在於最尖端科技、政策改革和新型合作模式所驅動的變革性變化。定序技術的最新進展，包括新世代定序平台和攜帶式照護現場設備，正在顯著降低時間和成本，實現即時微生物分析，並促進分散式診斷。

評估 2025 年美國貿易關稅對人類微生物組領域供應鏈、成本結構和創新動態的累積影響。

美國將於2025年實施貿易關稅​​，這為人類微生物組領域帶來了複雜的挑戰和戰略考量。對關鍵投入品（例如特殊試劑、高精度定序設備和聚合酵素鏈鎖反應(PCR) 組件）徵收的進口關稅，正推高診斷設備和實驗室耗材的生產成本。這些成本上漲迫使製造商重組供應鏈，並探索在地採購和近岸外包策略，以降低關稅波動帶來的風險。

透過按類型、目標微生物組部位、應用和最終用戶進行關鍵市場細分分析，我們揭示了多樣化的市場動態。

對市場區隔的深入理解，能夠幫助我們洞悉整個人類微生物組價值鏈中成長機會與競爭壓力交會之處。按產品類型分類，市場涵蓋了抗生素（其在調節微生物群落方面持續發揮關鍵作用）以及各種診斷儀器，例如高通量微生物定序平台和基於PCR的快速檢測方法。同時，以菊糖和寡糖為中心的益生元領域，凸顯了靶向基材在滋養有益微生物方面的重要性；而益生菌和合合益素領域也在蓬勃發展，它們將活性細菌與輔助纖維相結合。

本報告重點分析了美洲、歐洲、中東和非洲以及亞太地區的關鍵區域見解，揭示了地理趨勢和成長催化劑。

全球微生物組產業在不同地區的採用率、法規結構和研發投入方面存在差異，從而塑造了不同的成長軌跡。在美洲，精準醫療的完善基礎設施和領先的學術研究中心正在加速臨床檢驗研究，尤其是在腸道和皮膚微生物組領域。北美地區創業投資和支持性監管政策的匯聚，正推動著專注於創新治療方法和直接面對消費者的診斷服務的Start-Ups公司蓬勃發展。

分析塑造人類微生物組領域競爭動態的關鍵產業參與者的策略、合作關係和技術創新。

人類微生物組領域的競爭格局由眾多參與者構成，既有老牌製藥巨頭，也有專注於特定領域的生物技術公司和敏捷的診斷設備創新者。現有醫療機構正透過收購微生物組療法Start-Ups和與學術機構合作來拓展其產品線，並檢驗微生物組干預的新適應症。同時，早期公司也在建立策略夥伴關係，以加速臨床開發並擴大其在代謝性疾病和感染疾病等特定治療領域的市場佔有率。

我們提供切實可行的策略建議，幫助產業領導者最佳化投資、降低風險並最大限度地掌握新機會。

為了克服人類微生物組生態系統的複雜性並最大限度地提高創新投資回報，產業領導者應採取多管齊下的策略方法。首先，透過整合診斷、補充劑和治療產品，實現產品系列多元化，可以減少對單一收入來源的依賴，並在臨床和消費者管道中創造交叉銷售機會。此外，透過與合約研究組織 (CRO) 和學術聯盟建立合作關係，加速生物標記的發現和臨床檢驗，可以進一步增強這種全面的市場定位。

提出調查方法，該方法結合了對專家的直接訪談、二手資料分析和高級分析框架，以確保獲得可靠的見解。

本執行摘要的調查方法整合了多層次的資料收集和分析，以確保獲得可靠且可操作的洞見。主要研究包括對高階主管、學術意見領袖和臨床醫生進行深入訪談，以了解他們對技術進步、監管趨勢和商業策略的第一手觀點。此外，還輔以二手研究，包括對已發表文獻、監管指導文件、行業白皮書和專利申請的全面審查。

本執行摘要概述了相關人員的關鍵趨勢和未來發展方向，重申了策略重點，並提供了全面的人類微生物組的概述。

總之，充滿活力的人類微生物組研究和商業化領域為診斷、治療和健康應用提供了前所未有的創新機會。本概述闡明了微生物群落的基本作用，重點介紹了技術和政策方面的變革性變化，並分析了近期貿易關稅對成本結構和供應鏈的影響。透過將這些研究結果與詳細的市場區隔和區域框架結合，相關人員可以更好地調整其策略，使其更符合市場實際情況和患者需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：人類微生物組市場：按類型分類

  • 抗生素
  • 診斷設備
    • 微生物組定序設備
    • 基於PCR的診斷
  • 益生元
    • 菊糖
    • 寡糖
  • 益生菌
  • 合益素

第9章：按微生物組分類的人類微生物組市場

  • 腸道微生物組
  • 鼻腔與呼吸道微生物組
  • 口腔微生物組
  • 皮膚微生物組
  • 陰道微生物組

第10章：人類微生物組市場：依應用領域分類

  • 診斷
    • 生物標記發現
    • 臨床診斷
    • 伴隨診斷
  • 補充
  • 治療藥物
    • 消化系統疾病
    • 感染疾病
    • 代謝性疾病
    • 皮膚病

第11章 人類微生物組市場：依最終用戶分類

  • 診斷檢測實驗室
  • 居家照護設施
  • 醫院和診所
  • 製藥和生物技術公司
  • 研究機構

第12章：人類微生物組市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：人類微生物組市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：人類微生物組市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國人類微生物組市場

第16章：中國人類微生物組市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AOBiome, LLC
  • Axial Therapeutics, Inc.
  • BioHM Health Inc.
  • BiomeSense, Inc.
  • DuPont de Nemours, Inc.
  • Enterome Bioscience
  • Ferring BV
  • Finch Therapeutics Group, Inc.
  • Illumina, Inc.
  • Infinant Health Inc.
  • Intralytix, Inc.
  • Merck KGaA
  • Metabiomics Corporation
  • Osel Inc.
  • Pendulum Therapeutics
  • Synlogic, Inc.
  • Synthetic Biologics, Inc.
  • Viome Life Sciences, Inc.
  • Yakult Honsha Co., Ltd.
Product Code: MRR-430D42AA0FCD

The Human Microbiome Market was valued at USD 2.41 billion in 2025 and is projected to grow to USD 2.98 billion in 2026, with a CAGR of 24.83%, reaching USD 11.40 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.41 billion
Estimated Year [2026] USD 2.98 billion
Forecast Year [2032] USD 11.40 billion
CAGR (%) 24.83%

Uncovering the Human Microbiome Landscape Through a Comprehensive Introduction Highlighting Its Fundamental Roles, Historical Evolution, and Strategic Importance

The human microbiome has swiftly evolved from a niche scientific curiosity to a foundational element in understanding human health, disease prevention, and therapeutic innovation. This comprehensive introduction unpacks how the complex communities of microorganisms residing in and on the human body influence immune modulation, metabolic regulation, and neurological pathways. By examining seminal discoveries and key milestones in microbiome research, readers can appreciate the journey from early culture-based studies to high-throughput sequencing and multi-omics integrations.

Transitions within this field underscore the importance of interdisciplinary collaboration, as clinicians, microbiologists, bioinformaticians, and industry stakeholders converge to translate laboratory insights into real-world applications. This section establishes the essential context for the subsequent analysis by highlighting the microbiome's multifaceted role in diagnostics, supplements, and therapeutics. It sets the stage for exploring how foundational knowledge of microbial interactions is now driving precision medicine, personalized nutrition strategies, and novel drug discovery paradigms.

By grounding the executive summary in both historical perspective and contemporary relevance, this introduction ensures that decision-makers, investors, and research leaders gain a cohesive understanding of why the human microbiome continues to redefine the boundaries of healthcare innovation.

Identifying the Transformative Shifts Revolutionizing the Human Microbiome Landscape with Technological Breakthroughs Policy Advances and Strategic Collaborations

At the heart of the human microbiome's rapid evolution are transformative shifts fueled by cutting-edge technologies, policy reforms, and novel collaborative models. Recent advancements in sequencing technologies, including next-generation platforms and portable point-of-care devices, have drastically reduced turnaround times and costs, enabling real-time microbial profiling and fostering decentralized diagnostics.

Parallel to these technological breakthroughs, regulatory bodies have begun to establish clearer frameworks for microbiome-based products, particularly in the arenas of companion diagnostics and live biotherapeutic approvals. Evolving guidelines for clinical trials and quality assurance are streamlining pathways to market, incentivizing pharmaceutical and biotechnology entities to invest in pipeline expansion and strategic partnerships.

Equally impactful are cross-sector alliances that unite academic institutions, contract research organizations, and industry participants to co-develop standardized protocols for data sharing, analytical validation, and clinical applicability. These collaborations are redefining value chains, enabling stakeholders to transition from siloed research endeavors to integrated innovation ecosystems. Consequently, organizations that adapt to these shifts-by investing in agile methodologies, forging interdisciplinary alliances, and aligning with emergent regulations-are positioned to lead the next wave of microbiome discoveries.

Assessing the Cumulative Impact of 2025 United States Trade Tariffs on Supply Chains, Cost Structures, and Innovation Dynamics in Human Microbiome Sector

The implementation of United States trade tariffs in 2025 has introduced a complex array of challenges and strategic considerations for the human microbiome sector. Import duties on key inputs such as specialized reagents, high-precision sequencing instruments, and polymerase chain reaction components have exerted upward pressure on production costs for diagnostic devices and laboratory consumables. These cost inflations are prompting manufacturers to reevaluate supply chain configurations and consider localized sourcing or near-shoring strategies to mitigate exposure to tariff volatility.

Moreover, the cumulative effect of increased import duties has compelled stakeholders to scrutinize long-term partnerships with international suppliers, renegotiate contracts, and assess total landed costs for raw materials. In parallel, research and development budgets are being recalibrated to accommodate these additional expenses, which may impact the pace of innovation in areas such as live biotherapeutics, next-generation sequencing assays, and novel probiotic formulations.

Despite these headwinds, some organizations are leveraging tariff-driven disruption as an impetus for reshoring critical manufacturing processes and strengthening domestic supply resilience. By investing in local production of key reagents and equipment, companies can not only offset tariff burdens but also accelerate regulatory compliance timelines and reinforce quality control frameworks. Ultimately, the sector's ability to adapt procurement, production, and partnership strategies will determine how effectively it weathers the evolving trade landscape and sustains momentum in microbial research and commercialization.

Unveiling Critical Segmentation Insights by Type Target Microbiome Site Application and End User to Illuminate Diverse Market Dynamics

A granular understanding of market segmentation offers indispensable clarity into where growth opportunities and competitive pressures converge across the human microbiome value chain. By type, the market encompasses antibiotics, which continue to play a critical role in modulating microbial populations, as well as diagnostic devices that range from high-throughput microbiome sequencing platforms to rapid PCR-based assays. Meanwhile, the prebiotic category, anchored by inulin and oligosaccharides, underscores the importance of targeted substrates in nourishing beneficial microorganisms, complemented by the growing fields of probiotics and synbiotics that blend live cultures with supportive fibers.

Exploring the segmentation based on target microbiome site reveals distinct research and commercial pathways: the gut microbiome remains the largest focus of clinical and consumer interest, but substantial research initiatives now investigate nasal and respiratory, oral, skin, and vaginal microbial ecosystems. In parallel, application-based segmentation delineates three primary cohorts: diagnostics, which include early-stage biomarker discovery, clinical diagnostics, and companion diagnostic tools; supplements that range from functional foods to nutraceutical formulations; and therapeutics addressing gastrointestinal disorders, infectious diseases, metabolic syndromes, and dermatological conditions.

Lastly, end-user segmentation identifies diagnostic laboratories, home care settings, hospitals and clinics, pharmaceutical and biotechnology companies, and research institutes as the principal conduits through which microbiome solutions reach the market. Together, these layered perspectives illuminate the nuanced interplay between scientific innovation, clinical utility, and commercial viability within the dynamic microbiome ecosystem.

Highlighting Key Regional Insights across the Americas Europe Middle East and Africa and Asia Pacific to Illuminate Geographic Trends and Growth Catalysts

Regional nuances in adoption, regulatory frameworks, and research investments have created differentiated trajectories for growth across the global microbiome landscape. In the Americas, robust infrastructure in precision medicine and the presence of leading academic centers have accelerated clinical validation studies, particularly in the gut and skin microbiome domains. The convergence of venture capital investment and supportive regulatory guidance in North America has catalyzed a surge of startup activity focused on innovative therapeutics and direct-to-consumer diagnostic offerings.

Turning to Europe, the Middle East, and Africa, a mosaic of regulatory harmonization efforts and collaborative initiatives between public research institutions and private firms is fostering a fertile environment for microbiome research. Policymakers across the European Union are advancing frameworks for live biotherapeutic products, while Middle Eastern markets are exploring strategic partnerships to integrate microbiome technologies into national health programs. Meanwhile, select African research consortia are leveraging microbial diversity studies to address endemic health challenges and unlock novel bioactive compounds.

In the Asia-Pacific region, rapid digital health adoption, expansive population cohorts, and growing healthcare expenditures are fueling interest in both therapeutic interventions and functional foods designed to optimize microbial health. Governments and industry players are forging consortia to drive large-scale population studies, while regional manufacturers are scaling up production of prebiotic and probiotic formulations to serve local and export markets. These regional insights underscore the importance of tailored strategies that align with unique regulatory, clinical, and consumer contexts.

Analyzing Leading Industry Participants Strategies Collaborations and Technological Innovations Shaping Competitive Dynamics within the Human Microbiome

The competitive landscape of the human microbiome sector is defined by a diverse array of actors, ranging from established pharmaceutical giants to specialized biotechnology firms and agile diagnostic device innovators. Legacy healthcare organizations are expanding their pipelines through acquisitions of microbial therapeutics startups and collaborations with academic centers to validate novel indications for microbiome interventions. Concurrently, early-stage firms are securing strategic partnerships to accelerate clinical development and gain traction in target therapeutic areas such as metabolic disorders and infectious diseases.

Diagnostic device manufacturers, leveraging capabilities in high-throughput sequencing and PCR-based platforms, are investing in integrated solutions that combine sample-to-result workflows with advanced bioinformatics analytics. These endeavors are supported by contract research organizations that specialize in microbial assay validation and regulatory consulting, creating an ecosystem that facilitates faster market entry and quality compliance.

Supplement providers and nutraceutical companies are differentiating through proprietary formulations of prebiotics, probiotics, and synbiotics, often backed by human clinical trials and consumer wellness studies. This convergence of scientific rigor and consumer engagement is intensifying competition in the direct-to-consumer segment, compelling players to invest in digital health tools and personalized nutrition platforms. Collectively, the strategic maneuvers of these companies-spanning mergers, licensing agreements, and co-development programs-are reshaping the contours of competitive advantage within the microbiome arena.

Delivering Actionable Strategic Recommendations to Empower Industry Leaders Optimize Investments Mitigate Risks and Capitalize on Emerging Opportunities

To navigate the complexities of the human microbiome ecosystem and maximize return on innovation investments, industry leaders should pursue a multi-pronged strategic approach. First, diversifying product portfolios by integrating diagnostics, supplements, and therapeutics will reduce reliance on any single revenue stream and enable cross-selling opportunities across clinical and consumer channels. This holistic positioning can be further strengthened by forging alliances with contract research organizations and academic consortia to accelerate biomarker discovery and clinical validation.

Second, investing in regional manufacturing footprints and supply chain resilience is critical in light of evolving trade policies and input cost fluctuations. Establishing localized reagent production and scalable fermentation capabilities will safeguard against external disruptions while optimizing total cost of ownership and regulatory compliance timelines.

Third, adopting advanced analytical frameworks, including machine learning-driven microbial signature analysis and digital health integrations, will empower real-time decision-making and personalized treatment protocols. Combining these capabilities with patient engagement platforms enhances data collection and outcomes monitoring, fostering long-term value generation.

Finally, proactive engagement with regulatory stakeholders and participation in industry standardization initiatives will streamline approval pathways and bolster stakeholder confidence. By championing best practices for quality assurance and data transparency, organizations can solidify their reputations as trusted partners in the evolving human microbiome field.

Presenting a Research Methodology Combining Primary Expert Interviews Secondary Data Analysis and Advanced Analytical Frameworks to Ensure Robust Insights

The research methodology underpinning this executive summary integrates multiple layers of data collection and analysis to ensure robust, actionable insights. Primary research involved in-depth interviews with senior executives, academic thought leaders, and clinical practitioners to capture firsthand perspectives on technological advancements, regulatory trends, and commercial strategies. These qualitative inputs were complemented by secondary research, which encompassed a comprehensive review of published literature, regulatory guidance documents, industry white papers, and patent filings.

Data triangulation techniques were employed to validate emerging trends and reconcile discrepancies between conflicting data points. Advanced analytical frameworks, including cluster analysis of segmentation variables and scenario planning around trade tariff impacts, were applied to deepen the understanding of market dynamics. Comparative analyses across geographic regions and end-user categories further enriched the contextual narrative, enabling a balanced assessment of growth drivers and potential inhibitors.

Finally, an expert validation process engaged a panel of multidisciplinary advisors to review key findings, verify assumptions, and refine strategic recommendations. This rigorous, multi-stage approach ensures that the insights presented herein are grounded in empirical evidence and reflect the latest developments within the human microbiome landscape.

Summarizing the Comprehensive Human Microbiome Executive Summary to Reinforce Strategic Takeaways Critical Trends and the Path Forward for Stakeholders

In conclusion, the dynamic field of human microbiome research and commercialization offers unprecedented opportunities for innovation across diagnostics, therapeutics, and wellness applications. This summary has illuminated the foundational roles of microbial communities, highlighted transformative shifts in technology and policy, and dissected the implications of recent trade tariffs on cost structures and supply chains. By contextualizing these findings within detailed segmentation and regional frameworks, stakeholders can better align their strategies with market realities and patient needs.

The competitive landscape is being reshaped by strategic partnerships, mergers, and technological integrations that drive differentiation and accelerate time to market. Forward-thinking organizations that embrace diversified portfolios, invest in supply chain resilience, and leverage advanced analytics will be poised to lead the next wave of microbiome breakthroughs.

As this sector continues to evolve, ongoing collaboration between industry, academia, and regulatory authorities will be critical to translating scientific discovery into tangible health outcomes. The pathways outlined in this executive summary offer a strategic blueprint for navigating complexity and capitalizing on the transformative potential of the human microbiome.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Microbiome Market, by Type

  • 8.1. Antibiotics
  • 8.2. Diagnostic Devices
    • 8.2.1. Microbiome Sequencing Devices
    • 8.2.2. PCR-Based Diagnostics
  • 8.3. Prebiotics
    • 8.3.1. Inulin
    • 8.3.2. Oligosaccharides
  • 8.4. Probiotics
  • 8.5. Synbiotics

9. Human Microbiome Market, by Target Microbiome Site

  • 9.1. Gut Microbiome
  • 9.2. Nasal & Respiratory Microbiome
  • 9.3. Oral Microbiome
  • 9.4. Skin Microbiome
  • 9.5. Vaginal Microbiome

10. Human Microbiome Market, by Application

  • 10.1. Diagnostics
    • 10.1.1. Biomarker Discovery
    • 10.1.2. Clinical Diagnostics
    • 10.1.3. Companion Diagnostics
  • 10.2. Supplements
  • 10.3. Therapeutics
    • 10.3.1. Gastrointestinal Disorders
    • 10.3.2. Infections
    • 10.3.3. Metabolic Disorders
    • 10.3.4. Skin Disorders

11. Human Microbiome Market, by End User

  • 11.1. Diagnostic Laboratories
  • 11.2. Home Care Settings
  • 11.3. Hospitals & Clinics
  • 11.4. Pharmaceutical & Biotechnology Companies
  • 11.5. Research Institutes

12. Human Microbiome Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Human Microbiome Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Human Microbiome Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Human Microbiome Market

16. China Human Microbiome Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AOBiome, LLC
  • 17.6. Axial Therapeutics, Inc.
  • 17.7. BioHM Health Inc.
  • 17.8. BiomeSense, Inc.
  • 17.9. DuPont de Nemours, Inc.
  • 17.10. Enterome Bioscience
  • 17.11. Ferring B.V.
  • 17.12. Finch Therapeutics Group, Inc.
  • 17.13. Illumina, Inc.
  • 17.14. Infinant Health Inc.
  • 17.15. Intralytix, Inc.
  • 17.16. Merck KGaA
  • 17.17. Metabiomics Corporation
  • 17.18. Osel Inc.
  • 17.19. Pendulum Therapeutics
  • 17.20. Synlogic, Inc.
  • 17.21. Synthetic Biologics, Inc.
  • 17.22. Viome Life Sciences, Inc.
  • 17.23. Yakult Honsha Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMAN MICROBIOME MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HUMAN MICROBIOME MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY MICROBIOME SEQUENCING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY MICROBIOME SEQUENCING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY MICROBIOME SEQUENCING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PCR-BASED DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PCR-BASED DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PCR-BASED DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY INULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY INULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY INULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY OLIGOSACCHARIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY OLIGOSACCHARIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY OLIGOSACCHARIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PROBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PROBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SYNBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SYNBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SYNBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GUT MICROBIOME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GUT MICROBIOME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GUT MICROBIOME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY NASAL & RESPIRATORY MICROBIOME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY NASAL & RESPIRATORY MICROBIOME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY NASAL & RESPIRATORY MICROBIOME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY ORAL MICROBIOME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY ORAL MICROBIOME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY ORAL MICROBIOME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SKIN MICROBIOME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SKIN MICROBIOME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SKIN MICROBIOME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY VAGINAL MICROBIOME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY VAGINAL MICROBIOME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY VAGINAL MICROBIOME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SKIN DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SKIN DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY SKIN DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. GCC HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GCC HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. GCC HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 183. GCC HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 184. GCC HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. GCC HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 187. GCC HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 188. GCC HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. G7 HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. G7 HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. G7 HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 210. G7 HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 211. G7 HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 212. G7 HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. G7 HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 214. G7 HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 215. G7 HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. NATO HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. NATO HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. NATO HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 219. NATO HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 220. NATO HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 221. NATO HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. NATO HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 223. NATO HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 224. NATO HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL HUMAN MICROBIOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA HUMAN MICROBIOME MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA HUMAN MICROBIOME MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA HUMAN MICROBIOME MARKET SIZE, BY PREBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA HUMAN MICROBIOME MARKET SIZE, BY TARGET MICROBIOME SITE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA HUMAN MICROBIOME MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA HUMAN MICROBIOME MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA HUMAN MICROBIOME MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA HUMAN MICROBIOME MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)